Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "Phase 3 RUBY Trial - Dostarlimab + Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer - Analysis of PFS & OS Outcomes by Molecular Classification"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Mansoor Raza Mirza
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Mansoor Raza Mirza
Comments 0
Login to view comments.
Click here to Login
